Versiani M, Nardi A E, Figueira I L, Stabl M
Institute of Psychiatry, Federal University of Rio de Janeiro, Brazil.
Acta Psychiatr Scand Suppl. 1990;360:24-8. doi: 10.1111/j.1600-0447.1990.tb05320.x.
Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies. Pooled data from these studies, comprising 1656 patients, as well as the consideration of individual trials, show that moclobemide is far better tolerated than the TCAs. Its side effects mainly comprise mild degrees of nausea and dizziness at the beginning of treatment in a small proportion of patients. Age and sex do not affect the tolerability of moclobemide: it is equally well tolerated by elderly patients. In 2300 patients treated with moclobemide in doses up to 600 mg/day, without dietary restrictions, there was no tyramine-related hypertensive reaction. It is concluded that moclobemide may be the second-generation antidepressant doctors were waiting for--equally effective as the classical antidepressants but far better tolerated.
吗氯贝胺是一种新型的选择性、可逆性单胺氧化酶A抑制剂（RIMA），在众多对照研究中已与多种三环类抗抑郁药（TCA）进行了比较。这些研究（涉及1656名患者）的汇总数据以及对个别试验的考量表明，吗氯贝胺的耐受性远优于三环类抗抑郁药。其副作用主要包括一小部分患者在治疗开始时出现的轻度恶心和头晕。年龄和性别不影响吗氯贝胺的耐受性：老年患者对其耐受性同样良好。在2300名接受吗氯贝胺治疗、剂量高达600毫克/天且无饮食限制的患者中，未出现与酪胺相关的高血压反应。结论是，吗氯贝胺可能是医生们一直在等待的第二代抗抑郁药——与经典抗抑郁药效果相当，但耐受性要好得多。
